A review of opioid addiction genetics.
paper
Cited
Public
- Authors
- Crist, Richard C; Reiner, Benjamin C; Berrettini, Wade H
- Year
- 2019
- Journal
- Current opinion in psychology
- PMID
- 30118972
- DOI
- 10.1016/j.copsyc.2018.07.014
- PMCID
- PMC6368898
Opioid use disorder (OUD) affects millions of people worldwide and the risk of developing the disorder has a significant genetic component according to twin and family studies. Identification of the genetic variants underlying this inherited risk has focused on two different methods: candidate gene studies and genome-wide association studies (GWAS). The most studied candidate genes have included the mu-opioid receptor (OPRM1), the delta-opioid receptor (OPRD1), the dopamine D2 receptor (DRD2), and brain-derived neurotrophic factor (BDNF). Variants in these genes have been associated with relatively small, but reproducible, effects on OUD risk. More recently, GWAS have identified potential associations with variants in KCNG2, KCNC1, CNIH3, APBB2, and RGMA. In total the genetic associations identified so far explain only a small portion of OUD risk. GWAS of OUD is still in the early stages when compared to studies of other psychiatric disorders, such as schizophrenia, which have found many relevant variants with small effect sizes only after large meta-analyses. Substantial increases in cohort sizes will likely be necessary in the OUD field to achieve similar results. In addition, it will be important for future studies of OUD to incorporate rare variants, epigenetics, and gene × environment interactions into models in order to better explain the observed heritability.
No figures extracted from this document.
1–17 of 17
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
| Citation | PMID | DOI | Status |
|---|---|---|---|
| AutonA, , A global reference for human genetic variation. Nature, 2015 526(7571): p. 68–74.2643224510.1038/nature15393PMC4750478 | — | — | — |
| BeerB, , Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study. PLoS One, 2013 8(9): p. e75359.2408651410.1371/journal.pone.0075359PMC3783401 | — | — | — |
| BondC, , Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A, 1998 95(16): p. 9608–13.968912810.1073/pnas.95.16.9608PMC21386 | — | — | — |
| ChengCY, , Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res Mol Brain Res, 2005 140(1–2): p. 86–90.1610945210.1016/j.molbrainres.2005.07.008 | — | — | — |
| ChengZ, , Genome-wide Association Study Identifies a Regulatory Variant of RGMA Associated With Opioid Dependence in European Americans. Biol Psychiatry, 2018.10.1016/j.biopsych.2017.12.016PMC604118029478698 | — | — | — |
| CollerJK, , Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis. Pharmgenomics Pers Med, 2009 2: p. 9–19.23226031PMC3513197 | — | — | — |
| CrowleyJJ, , A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet, 2003 13(3): p. 169–73.1296074910.1097/00041444-200309000-00006 | — | — | — |
| DengXD, , Association between DRD2/ANKK1 TaqIA polymorphism and common illicit drug dependence: evidence from a meta-analysis. Hum Immunol, 2015 76(1): p. 42–51.2550025210.1016/j.humimm.2014.12.005 | — | — | — |
| DrippsIJ and JutkiewiczEM, Delta Opioid Receptors and Modulation of Mood and Emotion. Handb Exp Pharmacol, 2017.10.1007/164_2017_4228993835 | — | — | — |
| GelernterJ, , Genome-wide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biol Psychiatry, 2014 76(1): p. 66–74.2414388210.1016/j.biopsych.2013.08.034PMC3992201 | — | — | — |
| GlattSJ, , Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. Drug Alcohol Depend, 2007 90(2–3): p. 159–65.1741647010.1016/j.drugalcdep.2007.02.022PMC2012941 | — | — | — |
| HaerianBS, BDNF rs6265 polymorphism and drug addiction: a systematic review and meta-analysis. Pharmacogenomics, 2013 14(16): p. 2055–65.2427985910.2217/pgs.13.217 | — | — | — |
| HancockDB, , Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1. Biol Psychiatry, 2015 78(7): p. 474–84.2574437010.1016/j.biopsych.2015.01.003PMC4519434 | — | — | — |
| HouQF and LiSB, Potential association of DRD2 and DAT 1 genetic variation with heroin dependence. Neurosci Lett, 2009 464(2): p. 127–30.1966468610.1016/j.neulet.2009.08.004 | — | — | — |
| JiaW, , Polymorphisms of brain-derived neurotrophic factor associated with heroin dependence. Neurosci Lett, 2011 495(3): p. 221–4.2145853310.1016/j.neulet.2011.03.072 | — | — | — |
| KalsiG, , Genome-Wide Association of Heroin Dependence in Han Chinese. PLoS One, 2016 11(12): p. e0167388.10.1371/journal.pone.0167388PMC514787927936112 | — | — | — |
| KapurS, , A118g polymorphism in mu opioid receptor gene (oprm1): association with opiate addiction in subjects of Indian origin. J Integr Neurosci, 2007 6(4): p. 511–22.1818126610.1142/s0219635207001635 | — | — | — |
| KendlerKS, , Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry, 2000 57(3): p. 261–9.1071191210.1001/archpsyc.57.3.261 | — | — | — |
| KroslakT, , The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem, 2007 103(1): p. 77–87.1787763310.1111/j.1471-4159.2007.04738.x | — | — | — |
| KumarD, ChakrabortyJ, and DasS, Epistatic effects between variants of kappa-opioid receptor gene and A118G of mu-opioid receptor gene increase susceptibility to addiction in Indian population. Prog Neuropsychopharmacol Biol Psychiatry, 2012 36(2): p. 225–30.2213832510.1016/j.pnpbp.2011.10.018 | — | — | — |
| Le MerrerJ, , Impaired Hippocampus-Dependent and Facilitated Striatum-Dependent Behaviors in Mice Lacking the Delta Opioid Receptor. Neuropsychopharmacology, 2013.10.1038/npp.2013.1PMC362940023303070 | — | — | — |
| LevranO, , Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav, 2008 7(7): p. 720–9.1851892510.1111/j.1601-183X.2008.00410.xPMC2885890 | — | — | — |
| LiD, , Genome-wide association study of copy number variations (CNVs) with opioid dependence. Neuropsychopharmacology, 2015 40(4): p. 1016–26.2534559310.1038/npp.2014.290PMC4330517 | — | — | — |
| MengC, , Influence of brain-derived neurotrophic factor genetic polymorphisms on the ages of onset for heroin dependence in a Chinese population. Genet Test Mol Biomarkers, 2012 16(9): p. 1044–50.2285687110.1089/gtmb.2012.0016 | — | — | — |
| MitchellJM, , Intra-VTA deltorphin, but not DPDPE, induces place preference in ethanol-drinking rats: distinct DOR-1 and DOR-2 mechanisms control ethanol consumption and reward. Alcohol Clin Exp Res, 2014 38(1): p. 195–203.2403346910.1111/acer.12246 | — | — | — |
| NagayaD, , A118G mu opioid receptor polymorphism among drug addicts in Malaysia. J Integr Neurosci, 2012 11(1): p. 117–22.2274478710.1142/S0219635212500082 | — | — | — |
| NelsonEC, , Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. Addict Biol, 2012.10.1111/j.1369-1600.2012.00445.xPMC386754222500942 | — | — | — |
| NelsonEC, , Evidence of CNIH3 involvement in opioid dependence. Mol Psychiatry, 2016 21(5): p. 608–14.2623928910.1038/mp.2015.102PMC4740268 | — | — | — |
| NielsenDA, , Genome-wide association study identifies genes that may contribute to risk for developing heroin addiction. Psychiatr Genet, 2010 20(5): p. 207–14.2052058710.1097/YPG.0b013e32833a2106PMC3832188 | — | — | — |
| NielsenDA, , Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol Psychiatry, 2008 13(4): p. 417–28.1819571510.1038/sj.mp.4002147PMC3810149 | — | — | — |
| NikolovMA, , No evidence of association between 118A>G OPRM1 polymorphism and heroin dependence in a large Bulgarian case-control sample. Drug Alcohol Depend, 2011 117(1): p. 62–5.2127770910.1016/j.drugalcdep.2010.12.026PMC3128690 | — | — | — |
| OertelBG, , A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem, 2009 284(10): p. 6530–5.1911620410.1074/jbc.M807030200 | — | — | — |
| RandesiM, , Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence. Drug Alcohol Depend, 2016 168: p. 164–169.2766455410.1016/j.drugalcdep.2016.08.634PMC6842569 | — | — | — |
| RipkeS, Biological insights from 108 schizophrenia-associated genetic loci. Nature, 2014 511(7510): p. 421–7.2505606110.1038/nature13595PMC4112379 | — | — | — |
| Schwantes-AnTH, , Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. Behav Genet, 2016 46(2): p. 151–69.2639236810.1007/s10519-015-9737-3PMC4752855 | — | — | — |
| ShiJ, , Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat, 2002 19(4): p. 459–60.10.1002/humu.902611933204 | — | — | — |
| TanEC, , Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport, 2003 14(4): p. 569–72.1265788710.1097/00001756-200303240-00008 | — | — | — |
| TsouCC, , DRD2 and ANKK1 genes associate with late-onset heroin dependence in men. World J Biol Psychiatry, 2017: p. 1–11.10.1080/15622975.2017.137263028854834 | — | — | — |
| TsuangMT, , Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry, 1998 55(11): p. 967–72.981906410.1001/archpsyc.55.11.967 | — | — | — |
| VereczkeiA, , Multivariate analysis of dopaminergic gene variants as risk factors of heroin dependence. PLoS One, 2013 8(6): p. e66592.2384050610.1371/journal.pone.0066592PMC3696122 | — | — | — |
| WangN, , Association between dopamine D2 receptor gene polymorphisms and the risk of heroin dependence. Genet Mol Res, 2016 15(4).10.4238/gmr1504877227819741 | — | — | — |
| ZhangJ, , A 35.8 kilobases haplotype spanning ANKK1 and DRD2 is associated with heroin dependence in Han Chinese males. Brain Res, 2018 1688: p. 54–64.2955026810.1016/j.brainres.2018.03.017 | — | — | — |
| ZhangY, , Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem, 2005 280(38): p. 32618–24.1604639510.1074/jbc.M504942200 | — | — | — |
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| <i>BDNF</i> gene polymorphisms and substance use disorders: a systematic review. | Peregud D et al. | — | 2026 | → |
| Approved medications for opioid use disorder : current update. | Soyka M | — | 2025 | → |
| Association Between the (GT)26 Allele in the GRIN2A Promoter and Opioid Use Disorder. | Xie X et al. | — | 2025 | → |
| Burden of Substance Use Disorders in the Middle East and North Africa from 1990 to 2019. | Darijani SR et al. | — | 2025 | → |
| Comparative mRNA profile analysis from NAc of adolescent male mice after binge-like alcohol exposure eliciting deficits in context fear extinction learning. | Lloret Torres ME et al. | — | 2025 | → |
| Genetic and Epigenetic Approaches to Opioid Use Disorder. | Ranadeva ND et al. | — | 2025 | → |
| Genome-wide association study reveals multiple loci for nociception and opioid consumption behaviors associated with heroin vulnerability in outbred rats. | Kuhn BN et al. | — | 2025 | → |
| Opioid Use Disorders: Prevention, Diagnosis, and Treatment Strategies to Mitigate Addiction Risks. | Agarwal U et al. | — | 2025 | → |
| Pharmacogenetic guided drug therapy - how to deal with phenoconversion in polypharmacy. | Stingl JC et al. | — | 2025 | → |
| Pharmacogenomic and Pharmacomicrobiomic Aspects of Drugs of Abuse. | Borrego-Ruiz A et al. | — | 2025 | → |
| Similarities and Differences in Genetics. | Liu W et al. | — | 2025 | → |
| The addictive process of opioids: current and novel interventions in opioid use disorder. | Duerksen J et al. | — | 2025 | → |
| Utility of Candidate Genes From an Algorithm Designed to Predict Genetic Risk for Opioid Use Disorder. | Davis CN et al. | — | 2025 | → |
| Whole-exome sequencing study of opioid dependence offers novel insights into the contributions of exome variants. | Wang L et al. | — | 2025 | → |
| A Conceptual Analysis of Opioid Use Disorder in Chronic Noncancer Pain Using Rodger's Evolutionary Approach. | Kyei EF et al. | — | 2024 | → |
| Effect of Transcranial Direct Current Stimulation on Craving, Cognitive Functions, and Serum Brain-Derived Neurotrophic Factor Level in Individuals on Maintenance Treatment for Opioid Use Disorder, A Randomized Sham-Controlled Trial. | Borzooee B et al. | — | 2024 | → |
| Epigenetic and sex differences in opioid use disorder in chronic pain: A real-world study linked with OPRM1 DNA methylation. | Agulló L et al. | — | 2024 | → |
| [Family-focused treatment approaches for drug-addicted parents]. | Koopmann A et al. | — | 2024 | → |
| Fibromyalgia is associated with increased odds of prior pain-precipitated relapse among non-treatment-seeking individuals with opioid use disorder. | Hall OT et al. | — | 2024 | → |
| Genetic and non-genetic predictors of risk for opioid dependence. | Na PJ et al. | — | 2024 | → |
| Genetic background and sex influence somatosensory sensitivity and oxycodone analgesia in the Hybrid Rat Diversity Panel. | Duffy EP et al. | — | 2024 | → |
| Genetic Variants Linked to Opioid Addiction: A Genome-Wide Association Study. | Panday SK et al. | — | 2024 | → |
| Is There a Natural, Non-addictive, and Non-anti-reward, Safe, Gene-based Solution to Treat Reward Deficiency Syndrome? KB220 Variants vs GLP-1 Analogs. | Modestino EJ et al. | — | 2024 | → |
| Modelling the progression of illicit substance use patterns from real-world evidence. | Tummala HP et al. | — | 2024 | → |
| Opioid trail: Tracking contributions to opioid use disorder from host genetics to the gut microbiome. | Duffy EP et al. | — | 2024 | → |
| Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females. | Sprague JE et al. | — | 2024 | → |
| Sex and genetic background influence intravenous oxycodone self-administration in the hybrid rat diversity panel. | Duffy EP et al. | — | 2024 | → |
| Solving the Global Opioid Crisis: Incorporating Genetic Addiction Risk Assessment with Personalized Dopaminergic Homeostatic Therapy and Awareness Integration Therapy. | Zeine F et al. | — | 2024 | → |
| A novel tetra-primer ARMS-PCR for genotyping of the OPRM1 gene rs1799971 variant associated with opioid use disorders. | Wijekumar PJ et al. | — | 2023 | → |
| Fibromyalgia predicts increased odds of pain-related addiction exacerbation among individuals with pain and opioid use disorder. | Hall OT et al. | — | 2023 | → |
| Functional genomic mechanisms of opioid action and opioid use disorder: a systematic review of animal models and human studies. | Falconnier C et al. | — | 2023 | → |
| Genetic Correlates as a Predictor of Bariatric Surgery Outcomes after 1 Year. | Thanos PK et al. | — | 2023 | → |
| Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments. | Barrett JE et al. | — | 2023 | → |
| Specificity in genetic and environmental risk for prescription opioid misuse and heroin use. | Dash GF et al. | — | 2023 | → |
| Accelerating Opioid Use Disorders Research by Integrating Multiple Data Modalities. | Bianchi SB et al. | — | 2022 | → |
| Acute opioid responses are modulated by dynamic interactions of <i>Oprm1</i> and <i>Fgf12</i> | Lemen PM et al. | — | 2022 | — |
| Altered Expression of Genes Associated with Major Neurotransmitter Systems in the Reward-Related Brain Regions of Mice with Positive Fighting Experience. | Smagin DA et al. | — | 2022 | → |
| Analyses of polymorphisms of intron 2 of OPRK1 (kappa-opioid receptor gene) in association with opioid and cocaine dependence diagnoses in an African-American population. | Yuferov V et al. | — | 2022 | → |
| Central sensitization in opioid use disorder: a novel application of the American College of Rheumatology Fibromyalgia Survey Criteria. | Hall OT et al. | — | 2022 | → |
| CircTmeff-1 in the nucleus accumbens regulates the reconsolidation of cocaine-associated memory. | Shen Q et al. | — | 2022 | → |
| CpH methylome analysis in human cortical neurons identifies novel gene pathways and drug targets for opioid use disorder. | Nagamatsu ST et al. | — | 2022 | → |
| Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci with predominant effects in brain regions associated with addiction. | Kember RL et al. | — | 2022 | → |
| Epigenetic Modulation of Opioid Receptors by Drugs of Abuse. | Reid KZ et al. | — | 2022 | → |
| Fentanyl-induced acute and conditioned behaviors in two inbred mouse lines: Potential role for Glyoxalase. | Harp SJ et al. | — | 2022 | → |
| Improving Uptake of Emergency Department-initiated Buprenorphine: Barriers and Solutions. | Kelly TD et al. | — | 2022 | → |
| Multi-trait genome-wide association study of opioid addiction: OPRM1 and beyond. | Gaddis N et al. | — | 2022 | → |
| Neurodevelopmental origins of substance use disorders: Evidence from animal models of early-life adversity and addiction. | Levis SC et al. | — | 2022 | → |
| Positive associations between cannabis and alcohol use polygenic risk scores and phenotypic opioid misuse among African-Americans. | Rabinowitz JA et al. | — | 2022 | → |
| Prenatal Effects of Nicotine on Obesity Risks: A Narrative Review. | White O et al. | — | 2022 | → |
| Unique and joint associations of polygenic risk for major depression and opioid use disorder with endogenous opioid system function. | Love T et al. | — | 2022 | → |
| Zhx2 Is a Candidate Gene Underlying Oxymorphone Metabolite Brain Concentration Associated with State-Dependent Oxycodone Reward. | Beierle JA et al. | — | 2022 | → |
| A systems omics-based approach to decode substance use disorders and neuroadaptations. | Veerappa A et al. | — | 2021 | → |
| Cost-utility analysis of single nucleotide polymorphism panel-based machine learning algorithm to predict risk of opioid use disorder. | Mallow PJ et al. | — | 2021 | → |
| Differential behavioral functioning in the offspring of rats with high vs. low self-administration of the opioid agonist remifentanil. | Rezvani AH et al. | — | 2021 | → |
| Drug repurposing for opioid use disorders: integration of computational prediction, clinical corroboration, and mechanism of action analyses. | Zhou M et al. | — | 2021 | → |
| Early Life Stress and Risks for Opioid Misuse: Review of Data Supporting Neurobiological Underpinnings. | Oswald LM et al. | — | 2021 | → |
| Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry. | Sanchez-Roige S et al. | — | 2021 | → |
| Genome-Wide Correlation of DNA Methylation and Gene Expression in Postmortem Brain Tissues of Opioid Use Disorder Patients. | Liu A et al. | — | 2021 | → |
| Heritable variation in locomotion, reward sensitivity and impulsive behaviors in a genetically diverse inbred mouse panel. | Bailey LS et al. | — | 2021 | → |
| Opioid Addiction and Opioid Receptor Dimerization: Structural Modeling of the OPRD1 and OPRM1 Heterodimer and Its Signaling Pathways. | Wu B et al. | — | 2021 | → |
| Overview of Genetic Analysis of Human Opioid Receptors. | Spampinato SM | — | 2021 | → |
| Population-specific genetic background for the OPRM1 variant rs1799971 (118A>G): implications for genomic medicine and functional analysis. | Levran O et al. | — | 2021 | → |
| Review and Consensus on Pharmacogenomic Testing in Psychiatry. | Bousman CA et al. | — | 2021 | → |
| Reviewing pharmacogenetics to advance precision medicine for opioids. | Magarbeh L et al. | — | 2021 | → |
| The Developmental Origins of Opioid Use Disorder and Its Comorbidities. | Levis SC et al. | — | 2021 | → |
| The Genomics of Opioid Addiction Longitudinal Study (GOALS): study design for a prospective evaluation of genetic and non-genetic factors for development of and recovery from opioid use disorder. | Heil J et al. | — | 2021 | → |
| The prospective association between illicit drug use and nonprescription opioid use among vulnerable adolescents. | Pike JR et al. | — | 2021 | → |
| The role of sex chromosomes and sex hormones in vocal learning systems. | Choe HN et al. | — | 2021 | → |
| An update on the role of common genetic variation underlying substance use disorders. | Johnson EC et al. | — | 2020 | → |
| Association of OPRM1 Functional Coding Variant With Opioid Use Disorder: A Genome-Wide Association Study. | Zhou H et al. | — | 2020 | → |
| Further evidence for the association of <i>GAL</i>, <i>GALR1</i> and <i>NPY1R</i> variants with opioid dependence. | Randesi M et al. | — | 2020 | → |
| Novel Targets to Treat Depression: Opioid-Based Therapeutics. | Browne CA et al. | — | 2020 | → |
| Opioid use and schizophrenia. | Li KJ et al. | — | 2020 | → |
| Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome. | Jones HE et al. | — | 2019 | → |
| Combating opioid addiction and abuse-2 ways to effectively intervene in the cycle of addiction through pharmacogenomics. | J Marcalus S et al. | — | 2019 | → |
| Current status of opioid addiction treatment and related preclinical research. | Kreek MJ et al. | — | 2019 | → |
| Epidemiology of the U.S. opioid crisis: the importance of the vector. | Compton WM et al. | — | 2019 | → |
| Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. | Burns JA et al. | — | 2019 | → |